About the CTEPH.com Editorial Board
CTEPH.com is supported by Bayer HealthCare. Bayer is committed to advancing CTEPH best practices and to contributing to enhanced understanding of CTEPH throughout the healthcare community. Toward that end, CTEPH.com has enlisted an editorial board of eminent experts in CTEPH.
The editorial board members play several roles on CTEPH.com:
- To guide the overall direction of CTEPH.com
- To suggest topics, cases, and features for development on CTEPH.com
- To review materials to be included on the site for medical accuracy and clinical relevance
- To contribute their own work to the collection of materials contained on the site
- To narrate educational videos explaining various aspects of CTEPH
Under the expert guidance of the editorial board, CTEPH.com will bring you up-to-date, clinically relevant information about CTEPH, with updates throughout the year. We hope you will visit CTEPH.com again soon to see what’s new.
William R. Auger, MD
William R. Auger, MD, is Professor of Clinical Medicine and Director of Academic Affairs for the Pulmonary PTE Program in the Division of Pulmonary and Critical Care Medicine at the University of California, San Diego (UCSD).
Dr. Auger earned his medical degree from the University of Rochester School of Medicine, New York; completed his residency at Strong Memorial Hospital, Rochester, New York; and completed a fellowship at UCSD. He is board certified in Internal Medicine and Pulmonary Medicine, and his particular clinical interests include chronic thromboembolic pulmonary hypertension and other large-vessel pulmonary vascular disorders.
Dr. Auger has focused on the natural history of chronic thromboembolic disease, along with the evaluation and management of patients with this unique disorder. His work has contributed to the characterization of the acute, high-permeability lung injury experienced by patients following surgical removal of their chronic thromboembolic lesions. Dr. Auger is also pursuing investigations involving the diagnostic approach to patients with pulmonary thromboembolic disease. Dr. Auger has authored numerous publications on reperfusion lung injury, chronic thromboembolic pulmonary hypertension, and pulmonary thromboendarterectomy in such journals as Chest, Circulation, the American Journal of Cardiology, and the American Journal of Respiratory and Critical Care Medicine.
Raymond L. Benza, MD*
Raymond L. Benza, MD, is a Professor of Medicine at Temple University, College of Medicine, in Philadelphia, Pennsylvania, and Program Director for the Advanced Heart Failure, Transplantation, Mechanical Circulatory Support and Pulmonary Vascular Diseases group of the Division of Cardiovascular Diseases at Allegheny General Hospital, Allegheny Health Network in Pittsburgh. He holds the James Magovern Chair for Cardiovascular Research.
Dr. Benza graduated cum laude from Emory University in Atlanta, Georgia, and received his medical degree from the University of Florida in Gainesville. He performed his internship and residency at the University of Michigan in Ann Arbor and served as the Chief Cardiology Fellow at the University of Alabama at Birmingham, later serving as a faculty member there.
Dr. Benza is a member of the Scientific Leadership Council of the Pulmonary Hypertension Association and former Chair of the Pulmonary Hypertension Council for the International Society of Heart and Lung Transplantation. His primary clinical interests are in the evaluation and treatment of advance congestive heart failure, cardiac transplantation, and pulmonary arterial hypertension. Dr. Benza is a funded investigator for the National Institutes of Health and the American Heart Association for his work in cardiac transplantation and pulmonary arterial hypertension.
Richard N. Channick, MD*
Richard N. Channick, MD, is Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, and has been Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital in Boston since 2009.
Dr. Channick earned his undergraduate degree at Connecticut College, New London, and his medical degree at Temple University School of Medicine, Philadelphia, Pennsylvania, before completing a residency at University of Massachusetts Medical Center, Worcester, Massachusetts, and a fellowship at University of California San Diego Medical Center. He is board certified in Internal Medicine, Critical Care Medicine, and Pulmonary Disease.
Dr. Channick has published numerous articles in and is a frequent speaker on pulmonary hypertension. He has long-standing involvement with the Pulmonary Hypertension Association (PHA), presently serving as Chair of the group’s Scientific Leadership Council; previously he was editor-in-chief of Advances in Pulmonary Hypertension, PHA’s medical journal.
Paul R. Forfia, MD*
Paul R. Forfia, MD, began his faculty career at the Hospital of the University of Pennsylvania, Philadelphia, serving as the Director of the Pulmonary Hypertension Program. In 2013, Dr. Forfia was appointed as Associate Professor of Medicine and Director of the Pulmonary Vascular Disease, Right Heart Failure, and Pulmonary Thromboendarterectomy Program at Temple University Hospital, Philadelphia.
Dr. Forfia earned his master’s degree in Physiology and medical degree from New York Medical College in Valhalla, New York. He completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Heart Failure/Transplantation at Johns Hopkins Hospital, Baltimore, Maryland. Dr. Forfia also received additional training in pulmonary hypertension at Johns Hopkins.
Dr. Forfia’s clinical interests include pulmonary hypertension, right heart dysfunction, and the investigation of dyspnea. His research focuses on the noninvasive assessment of right heart and pulmonary vascular function as well as physiologic phenotyping of non-PAH forms of pulmonary hypertension. He serves as an editor to numerous high-impact journals and has published more than 60 manuscripts and book chapters, mostly in the areas of PH and right heart function.
Gustavo Heresi-Davila, MD*
Gustavo Heresi-Davila, MD, joined the staff of the Department of Pulmonary, Allergy, and Critical Care Medicine at Cleveland Clinic, Cleveland, Ohio, in 2008. He is currently the Medical Director of the Pulmonary Thromboendarterectomy Program there.
Dr. Heresi earned his medical degree at National University of San Agustin, Arequipa, Peru, then went on to a residency in Internal Medicine at Jackson Memorial Hospital/University of Miami in Florida, and a fellowship in Pulmonary and Critical Care Medicine at Cleveland Clinic.
Dr. Heresi’s specialties include pulmonary hypertension, chronic thromboembolic pulmonary hypertension, acute respiratory distress syndrome, pneumonia, pulmonary fibrosis, scleroderma, and sepsis. He is board certified in the fields of Internal Medicine, Critical Care Medicine, and Pulmonary Disease and has published more than 30 papers in the field of pulmonary hypertension.
Dr. Heresi has a long-standing clinical and research interest in pulmonary hypertension, with significant contributions in the field of biomarkers and risk prediction. He has received the 2003–2004 Student Inpatient Teaching Award and the 2005 Distinguished Medical Resident Award of the University of Miami and the 2012 CHEST Young Investigator Award.
Nick H. Kim, MD*
Nick H. Kim, MD, is Associate Clinical Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Diego (UCSD). He is Director of Pulmonary Vascular Medicine and of the PCCM Fellowship Training Program at UCSD.
Dr. Kim graduated from Harvard University, Cambridge, Massachusetts, and received his medical degree in 1994 from the University of Chicago Pritzker School of Medicine, Illinois. He completed his Internal Medicine internship and residency at the University of Chicago and a year of anesthesiology training at UCSF. After completing fellowship training in Pulmonary and Critical Care Medicine at UCSD in 2001, he joined the faculty specializing in pulmonary vascular medicine.
Dr. Kim’s clinical and research interests are in pulmonary hypertension and chronic thromboembolic disease. He is an investigator for numerous pulmonary hypertension clinical trials, has published in numerous peer-reviewed journals, and has lectured internationally on the subject of pulmonary hypertension.
Michael M. Madani, MD*
Michael M. Madani, MD, is Professor and Chief of Cardiovascular and Thoracic Surgery and Director of the Sulpizio Cardiovascular Center–Surgery at the University of California, San Diego (USCD), La Jolla. He is also the surgical director of the Pulmonary Endarterectomy program at UCSD.
Dr. Madani received his medical degree from University of Toronto, Canada, and completed his residency in general surgery at the Berkshire Medical Center, University of Massachusetts Medical School, and his advanced fellowship training in cardiovascular and thoracic surgery at UCSD. He is certified by the American Board of Surgery and the American Board of Thoracic Surgery.
Dr. Madani’s research interests at UCSD are focused on the surgical treatment for chronic thromboembolic pulmonary hypertension as well as outcomes of pulmonary endarterectomy for treating extreme thromboembolic pulmonary hypertension. He was an investigator in an ongoing national multicenter study devoted to establishing the United States CTEPH Registry, which is creating a national database of all patients with CTEPH. Dr. Mandani is also author of numerous publications on the surgical treatment of CTEPH and cardiac disease in peer-reviewed journals such as Journal of the American College of Cardiology, the American Journal of Surgery, the Journal of Thoracic and Cardiovascular Surgery, and the Annals of Thoracic Surgery.
Myung H. Park, MD, FACC*
Myung H. Park, MD is the Chief of the Heart Failure Division, Houston Methodist DeBakey Cardiology Associates in Houston, Texas. Her areas of clinical expertise include advanced heart failure and cardiac transplantation, pulmonary hypertension and right heart failure, CTEPH (chronic thromboembolic pulmonary hypertension), and mechanical circulatory support.
Dr. Park obtained her medical degree from Temple University Medical School and completed her residency in Internal Medicine at Temple University Hospital. She finished her cardiovascular fellowship training at the Virginia Commonwealth University and subsequently went to further her training by obtaining an advanced fellowship training in Heart Failure and Cardiac Transplantation at The Cleveland Clinic Foundation. Dr. Park served as the Director of Pulmonary Vascular Diseases Program and the Cardiac Care Unit at University of Maryland Medical Center in Baltimore, Maryland prior to joining the Houston Methodist team. She is certified in Cardiovascular Diseases and Advanced Heart Failure and Cardiac Transplantation.
Dr. Park is actively involved in multiple areas of clinical research. She is well published in the field of pulmonary hypertension, cardiac transplantation and heart failure. Her recently published manuscripts appear in the Journal of Heart and Lung Transplantation, Journal of American College of Cardiology, and many others. She is the past Editor-In-Chief for the Advances in Pulmonary Hypertension Journal and a member of the Senior Editorial Board for the Journal of Heart and Lung Transplantation. Dr. Park serves as a member of the Board of Directors for ISHLT (International Society of Heart and Lung Transplant) and serves on the Scientific Leadership Council for Pulmonary Hypertension Association.
Ivan M. Robbins, MD*
Ivan M. Robbins, MD, is Professor of Medicine and Director, Adult Pulmonary Hypertension Center, in the division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt University Medical Center, Nashville, Tennessee.
Beginning his education with an undergraduate degree from Brown University, Providence, Rhode Island, in 1981, Dr. Robbins went on to earn his medical degree from Case Western Reserve School of Medicine, Cleveland, Ohio, in 1991. He trained in Internal Medicine at Metrohealth Medical Center in Cleveland from 1991 to 1994 and completed a Pulmonary and Critical Care Fellowship at Vanderbilt University, Nashville, Tennessee, between 1994 to 1997.
Dr. Robbins is an expert in pulmonary vascular disease and is board certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine. He directs the adult Pulmonary Vascular Center at Vanderbilt University. His research has focused on new treatments for pulmonary arterial hypertension. He regularly participates in clinical research and clinical trials, and is a peer reviewer for a host of specialty respiratory and cardiology journals, as well as those in general medicine.
Victor F. Tapson, MD*
Victor F. Tapson, MD, is a board-certified Pulmonologist and researcher in the Division of Pulmonary/Critical Care Medicine at Cedars-Sinai Medical Center, Los Angeles, California, and a practicing physician with Cedars-Sinai Medical Group.
Prior to joining Cedars-Sinai, Dr. Tapson served as Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at Duke University Medical Center, Durham, North Carolina, and served as the Director of the Duke Pulmonary Vascular Disease Center. Dr. Tapson also held the position of Medical Director of the Duke Lung Transplant Center from 1992 until 2001.
Dr. Tapson’s primary interests are venous thromboembolism and pulmonary hypertension. He has also served on a number of national and international committees, including the Scientific Leadership Committee for the Pulmonary Hypertension Association, the World Health Organization Pulmonary Hypertension Working Group, and the American College of Chest Physicians Consensus Statement for Venous Thromboembolism. He has served as Chairman for the American Thoracic Society Consensus Statement and Clinical Practice Guidelines for the Diagnostic Approach to Acute Venous Thromboembolism.
Dr. Tapson’s work has been published in numerous academic peer-reviewed publications, including The New England Journal of Medicine, Annals of Internal Medicine, The Lancet, the Journal of Thrombosis and Haemostasis, and the Journal of the American College of Cardiology, Circulation.
*Are being compensated for their clinical expertise and contributions to this site.